Details:
Under the agreement, Searchlight Pharma will be responsible for obtaining and maintaining any regulatory approvals required to market and sell Twyneo (tretinoin), used for acne vulgaris and Epsolay (benzoyl peroxide), used for inflammatory lesions of rosacea, in Canada.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: SEARCHLIGHT PHARMA INC
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 06, 2023
Details:
Approval of EPSOLAY (benzoyl peroxide) is supported by data from Phase 3 trial, which demonstrated reduction in inflammatory lesions of rosacea by nearly 70% by end of both 12-week trials vs. 38-46% with vehicle.
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Epsolay
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Galderma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
TWYNEO is a topical cream containing a fixed‑dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Details:
Allergan Aesthetics will acquire Luminera's full dermal filler portfolio and R&D pipeline further enhancing Allergan Aesthetics' leading dermal filler portfolio with its JUVÉDERM® collection of fillers.
Lead Product(s): Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area: Dermatology Product Name: HArmonyCa
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Innovative Luminera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 07, 2020
Details:
Cutia will have an exclusive license to obtain regulatory approval and sell AMZEEQ. Foamix is to supply Cutia with the finished licensed products for clinical and commercial use.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cutia Therapeutics
Deal Size: $11.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement April 23, 2020
Details:
The Company intends to use the net proceeds from the Offering to fund pre-commercialization and launch activities for Epsolay® and Twyneo®, research and development activities and the remainder for working capital and other general corporate purposes.
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Epsolay
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 14, 2020